Vireo Gets More Firepower for M&A With Credit Facility Worth Up to $105 Million

Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) is adding another source of capital to an increasingly acquisition-driven growth strategy.

On Friday, the cannabis operator announced a new senior secured asset-based revolving credit facility with an initial commitment of $65 million that can potentially expand to $105 million.

The financing announcement came the same morning Vireo completed its approximately $49 million acquisition of 17 PharmaCann dispensaries in Colorado.

Taken together, the transactions offer a clearer picture of how Vireo is positioning its balance sheet as it rapidly expands through acquisitions across the U.S. cannabis industry.

A $65 Million Facility That Can Grow to $105 Million

Certain indirect non-cannabis subsidiaries of Vireo entered into a five-year senior secured asset-based revolving credit facility initially providing $65 million of commitments.

The facility can expand to $85 million and includes a $20 million accordion feature that could bring total commitments to as much as $105 million, subject to customary conditions.

That distinction matters: Vireo has not raised $105 million in cash. Rather, the agreement gives the company an initial $65 million revolving commitment with the ability to substantially increase its borrowing capacity.

Bank of Montreal is serving as administrative agent and collateral agent for the facility.

Borrowings are priced at either SOFR plus 1.75% to 2.00%, or a base rate plus 0.75% to 1.00%, depending on availability under the facility. Vireo can use proceeds for refinancing, working capital, capital expenditures, permitted acquisitions and other general corporate purposes.

For investors, the last category is particularly relevant given the pace at which Vireo has been assembling its portfolio.

Vireo Closes $49 Million PharmaCann Deal

Hours before announcing the financing, Vireo reported it had received the required regulatory approvals and completed its acquisition of PharmaCann’s Colorado retail assets.

The transaction adds 17 dispensaries and increases Vireo’s Colorado retail footprint to 56 operational locations. Total consideration was approximately $49 million, consisting of newly issued Vireo subordinate voting shares and the assumption of certain liabilities, rather than a $49 million cash payment.

Vireo has effectively been operating the acquired business for months.

Since March, the company had managed the PharmaCann locations under a management services agreement, allowing it to begin integrating operations before regulatory approval and formal closing. Vireo said it has already strengthened the local leadership team, changed product assortment, introduced its technology and operating systems, and made targeted capital investments in the business.

That agreement now ends, with the 17 locations becoming fully integrated into Vireo’s Colorado platform.

The company said it sees additional opportunities to improve performance and expand margins as integration continues.

Vireo Is Building Through M&A

The PharmaCann transaction is only one component of a much larger consolidation strategy.

Vireo acquired a controlling interest in the reorganized Schwazze business in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. It subsequently completed its merger with Eaze and acquired Hawthorne Gardening Company from Scotts Miracle-Gro.

More deals have followed.

In July, Vireo agreed to acquire cannabis assets from The Cannabist Company across Colorado, Illinois, Massachusetts, New Jersey and West Virginia for consideration of up to $35 million.

Days later, it announced an all-stock agreement to acquire Planet 13 Holdings.

The Planet 13 transaction would add significant operations in Nevada and Florida, as well as an Illinois dispensary. If completed alongside Vireo’s other pending transactions, the company expects to operate roughly 265 retail stores and dispensaries across 15 states.

Vireo’s expansion has therefore moved beyond individual acquisitions. The company is attempting to build a substantially larger multi-state platform through a combination of equity issuance, debt restructuring, seller financing and now additional revolving credit capacity.

The Capital Allocation Question

The structure of the PharmaCann transaction hints at Vireo’s strategy. Vireo did not need to fund the approximately $49 million purchase price entirely with cash, instead relying on subordinate voting shares and assumed liabilities. The management agreement also gave Vireo months to begin integrating the stores before formally taking ownership.

The new revolving facility adds another financing tool.

Rather than immediately drawing $105 million, Vireo now has access to an initial $65 million commitment that can potentially scale as its capital requirements evolve.

That flexibility could become increasingly important as the company absorbs acquired businesses, funds capital expenditures and pursues additional transactions.

It also introduces another variable investors will need to monitor: leverage.

Vireo reported $137.8 million in cash as of March 31, alongside $106.2 million in first-quarter revenue and $32.7 million in adjusted EBITDA. Its adjusted EBITDA margin reached 30.8%.

But those numbers predate several significant transactions completed or announced during the second quarter and afterward, making the company’s upcoming financial results particularly important for assessing the consolidated business.

What Investors Should Watch Next

Vireo is scheduled to report second-quarter financial results on August 11.

The report should provide investors with a better view of how the company’s rapidly changing portfolio is translating into revenue, margins, cash generation and balance-sheet requirements.

Integration will be especially important.

Acquiring stores can rapidly increase Vireo’s footprint, but shareholder value ultimately depends on what the company earns from those assets relative to the capital — and dilution — required to acquire and improve them.

The new credit facility gives management substantially more financial flexibility.

The next question is how effectively Vireo deploys it.